NORDICCTX-III
LIVE

Serial Number

79433974

Owner

Nordic Bioscience A/S

Attorney

Bradley M. Stohry

Filing Date

Aug 14, 2025

Add to watchlist:

No watchlists yet
View on USPTO

NORDICCTX-III Trademark

Serial Number: 79433974

NORDICCTX-III is a trademark filed by Nordic Bioscience A/S on August 14, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Nordic Bioscience A/S (10 trademarks)

Herlev Hovedgade 205-207

Entity Type: 99

Trademark Details

Filing Date

August 14, 2025

Registration Date

Not Registered

Published for Opposition

August 25, 2026

Goods & Services

Diagnostic biomarker reagents for medical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; diagnostic biomarker assays to identify disease activity for medical use; diagnostic biomarker assays for medical use to quantify disease activity; diagnostic biomarker assays for medical use to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for testing bodily fluids for use in disease detection, disease analysis and quantifying disease activity; diagnostic agents for medical use; diagnostic reagents for medical use; clinical diagnostic agents; clinical diagnostic reagents for medical use; diagnostic preparations, diagnostic substances and diagnostic materials for medical purposes; medical diagnostic test strips for testing samples for the presence of biomarkers; diagnostic preparations for medical purposes

Design and development of blood-based biomarker assays for the identification, quantification and analysis of disease activity; design and development of diagnostic biomarker reagents for medical purposes, for pharmaceutical purposes and for scientific purposes; design and development of biochemical and pharmaceutical assays and medical assays; design and development of biomarkers for individual use or combined for the tracking of tissue formation, development or tissue degradation; pharmaceutical and scientific research in the fields of biomarkers and the detection of biomarkers; medical research, namely, identification of predictive and prognostic biomarkers for clinical trials; medical research, namely, identifying patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to clinical trials; scientific research in the nature of conducting clinical trials for others; medical research, namely, analysis of pharmacodynamic data; medical research, namely, analysis of data relating to biomarkers; development of diagnostic preparations for medical purposes, diagnostic equipment and diagnostic tests; medical research laboratory services relating to clinical testing services for others; providing reagent sample testing and diagnostic services for others for scientific research purposes; medical research services, namely, testing services relating to the tracking and measurement of biomarkers; medical research services, namely, testing samples for the presence of biomarkers; scientific laboratory services; medical research laboratory services; medical research laboratories; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research services involving experimentation, development, and analysis

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 5, 2026 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 5, 2026 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 27, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 17, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 17, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 17, 2026 TROA
REFUSAL PROCESSED BY IB
Feb 19, 2026 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 3, 2026 RFCS
REFUSAL PROCESSED BY MPU
Feb 3, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 8, 2026 RFCR
NON-FINAL ACTION WRITTEN
Jan 7, 2026 CNRT
ASSIGNED TO EXAMINER
Dec 29, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 5, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 5, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 2, 2025 REPR